3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Precursor Cell Lymphoblastic Leukemia-Lymphoma
18
Leukemia
13
Burkitt Lymphoma
11
Prostatic Neoplasms
9
Lymphoma
6
Leukemia, Biphenotypic, Acute
6
Lymphoma, Large B-Cell, Diffuse
4
Lymphoma, Non-Hodgkin
3
Neoplasms
2
Multiple Myeloma
2
Lymphoma, Mantle-Cell
2
Lymphoma, Large-Cell, Immunoblastic
2
Lymphoma, Follicular
2
Hodgkin Disease
2
Down Syndrome
2
Dendritic Cell Sarcoma, Interdigitating
2
Stomatitis
1
Rhabdoid Tumor
1
Recurrence
1
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
1
Pancreatic Neoplasms
1
Oral Ulcer
1
Neoplasms, Plasma Cell
1
Lymphoma, T-Cell
1
Lymphoma, B-Cell, Marginal Zone
1
Lymphoma, B-Cell
1
Lung Neoplasms
1
Leukemia, Myeloid, Acute
1
Leukemia, Mast-Cell
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Interventions
Fulvestrant
2
ruxolitinib
1
ceterizine hydrochloride
1
capivasertib
1
benralizumab
1
Triamcinolone Acetonide
1
Tetracycline
1
Sirolimus
1
Prednisone
1
Panitumumab
1
Minocycline
1
Loperamide
1
Irinotecan
1
IFL protocol
1
Hydrocortisone
1
Gels
1
Erlotinib Hydrochloride
1
Doxycycline
1
Dapsone
1
Clindamycin
1
Alpelisib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Exanthema
×
Hydrocortisone
×
Clear all
NCT00473083
2017-04-04
LUTRAERL
British Columbia Cancer Agency
Phase 2
Completed
150 enrolled
13 charts